Centre for Reproductive Medicine, Tianjin Central Hospital of Gynecology Obstetrics, No. 156 Nankai San Ma Road, Tianjin, 300100, China.
BMC Pregnancy Childbirth. 2022 Apr 2;22(1):279. doi: 10.1186/s12884-022-04591-5.
Anti-Müllerian hormone (AMH) is used as a biomarker to estimate ovarian reserve. The relationship between AMH and early miscarriage of in vitro fertilization (IVF) is still inconclusive. This study aimed to explore whether serum AMH levels are associated with early miscarriage rates after in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) with fresh embryo transfer (ET).
This retrospective cohort study included 2246 patients undergoing their first oocyte retrievals for IVF/ICSI with fresh embryos transferred to Tianjin Central Hospital of Gynecology Obstetrics between May 2018 and March 2020. The serum AMH levels of the patients were measured within 12 months before the IVF/ICSI cycles. All women were divided into a low-AMH group, medium-AMH group and high-AMH group. Binary logistic regression was applied to confirm whether the serum AMH level was associated with the risk of early miscarriage independent of potential confounders, such as age, body mass index (BMI), duration of infertility, main diagnosis, history of internal medicine diseases, number of oocytes retrieved and high-quality embryo rate.
The early miscarriage rate was significantly lower in the medium-AMH group than in either the low-AMH or high-AMH group among young (< 35 years) women (P = 0.015). In women above 35 years of age, the early miscarriage rates in the three AMH groups were not significantly different. Young women with high serum AMH levels had a significantly higher risk of early miscarriage regardless of age or other potential confounders (adjusted odds ratio (OR) 2.382, 95% confidence interval (CI) 1.246 to 4.553, P = 0.009). The results remained similar after restricting the analysis to women without polycystic ovary syndrome (PCOS).
With a high AMH level, young women had a higher risk of early miscarriage than women with a medium AMH level in their first IVF/ICSI treatment. In young women, serum AMH levels were independently associated with the risk of early miscarriage after IVF-ET treatment. Serum AMH levels might be a valuable marker to estimate the risk of early miscarriage. It is worth noting to the clinical value of AMH.
抗苗勒氏管激素(AMH)被用作评估卵巢储备的生物标志物。AMH 与体外受精(IVF)早期流产的关系仍不确定。本研究旨在探讨血清 AMH 水平是否与新鲜胚胎移植(ET)后 IVF/卵胞浆内单精子注射(ICSI)的早期流产率有关。
这是一项回顾性队列研究,纳入 2018 年 5 月至 2020 年 3 月期间在天津中心妇产科医院行首次 IVF/ICSI 且新鲜胚胎移植的 2246 例患者。在 IVF/ICSI 周期前 12 个月内测量患者的血清 AMH 水平。所有女性分为低 AMH 组、中 AMH 组和高 AMH 组。应用二元逻辑回归来确认血清 AMH 水平是否与早期流产风险相关,且不受年龄、体质量指数(BMI)、不孕持续时间、主要诊断、内科疾病史、获卵数和优质胚胎率等潜在混杂因素的影响。
在年轻(<35 岁)女性中,中 AMH 组的早期流产率明显低于低 AMH 组或高 AMH 组(P=0.015)。在年龄>35 岁的女性中,三组 AMH 患者的早期流产率无显著差异。无论年龄大小或其他潜在混杂因素如何,血清 AMH 水平较高的年轻女性发生早期流产的风险显著升高(调整后的比值比(OR)2.382,95%置信区间(CI)1.246 至 4.553,P=0.009)。排除多囊卵巢综合征(PCOS)患者后,结果仍相似。
在首次 IVF/ICSI 治疗中,高 AMH 水平的年轻女性比中 AMH 水平的年轻女性发生早期流产的风险更高。在年轻女性中,血清 AMH 水平与 IVF-ET 治疗后早期流产的风险独立相关。血清 AMH 水平可能是评估早期流产风险的有价值标志物,值得注意的是 AMH 具有临床价值。